TABLE III.

Intravenous antiangiogenic therapy in non-small-cell lung cancer after disease progression

Agent and reference (study)	Design	Intervention	Pts (n)	ORR (%)	PFS (months)	OS (months)	Quality of life
Bevacizumab
Herbst et al.,200735	Randomized phase II	Docetaxel–pemetrexed with bevacizumab 15 mg/kg	40	12.5	4.8 HR: 0.66; 95% CI: 0.38 to 1.16	12.6 HR: 0.71; 95% CI: 0.41 to 1.21	Not assessed.
		Erlotinib with bevacizumab 15 mg/kg	39	17.9	4.4 HR: 0.72; 95% CI: 0.42 to 1.23	13.7 HR: 0.78; 95% CI: 0.46 to 1.31
		Docetaxel–pemetrexed with placebo	41	12.2	3.0	8.6
Herbst et al.,201136 (BeTa)	Phase III	Erlotinib with bevacizumab 15 mg/kg	319	13	3.4	9.3	Not assessed.
		Erlotinib with placebo	317	6	1.7 HR: 0.62; 95% CI: 0.52 to 0.75	9.2 HR: 0.97; 95% CI: 0.80 to 1.18
Cortot et al.,201637 (ULTIMATE)	Randomized phase III	Paclitaxel (weekly) with bevacizumab 10 mg/kg	111	22.5	5.4	9.9	Not assessed.
		Docetaxel	55	5.5 p=0.006	3.9 HR: 0.62; 95% CI: 0.44 to 0.87	11.4 HR: 1.15; p=0.49
Bennouna et al.,201740 (AVaALL)	Phase III	Chemotherapy with bevacizumab	485 in total	9.7	4.9 HR: 0.85; 90% CI: 0.72 to 1.0	11.9 HR: 0.84; 90% CI: 0.71 to 1.0
		Chemotherapy alone		6.7	3.8	10.2
Garon et al.,201438 (REVEL)	Phase III	Docetaxel with ramucirumab	628	23	4.5	10.5
		Docetaxel with placebo	625	14	3.0 HR: 0.76; 95% CI: 0.68 to 0.86	9.1 HR: 0.86; 95% CI: 0.75 to 0.98
Aflibercept
Ramlau et al.,201239 (VITAL)	Phase III	Docetaxel with aflibercept	456	23.3	5.2 HR: 0.82; 95% CI: 0.72 to 0.94	10.1 HR: 1.01; 95% CI: 0.87 to 1.17	No differences observed using the Lung Cancer Symptom Scale.
		Docetaxel with placebo	457	8.9	4.1	10.4

Pts = patients; ORR = objective response rate; PFS = progression-free survival; OS = overall survival; HR = hazard ratio; CI = confidence interval.